LISCure Biosciences develops bacteria-mediated immunotherapy that enhances the immune response specifically within tumor microenvironments to improve cancer treatment efficacy. This approach aims to increase patient outcomes by targeting and disrupting the mechanisms that allow cancer cells to evade immune detection.
Funding
$48M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often fail due to the tumor microenvironment's ability to suppress the immune system, allowing cancer cells to evade detection and destruction. Traditional methods of stimulating the immune response may not be effective within the tumor itself, limiting their overall efficacy.
Solution
LISCure Biosciences develops bacteria-mediated immunotherapies designed to enhance the immune response specifically within the tumor microenvironment. Their approach utilizes engineered microorganisms to modulate the immune system directly at the tumor site, aiming to overcome immune suppression and improve cancer treatment outcomes. The LISCure Microbiology-based Technology (LMT) platform facilitates the discovery and analysis of microorganism-based drug candidates through therapeutic screening, microbial optimization, and a microbiome database. This platform supports the development of both injectable bacteria-mediated cancer immunotherapies and oral microbiome therapeutics. LISCure's pipeline addresses areas of high unmet medical need, including oncology, liver diseases, neuroscience, and immunology, with several global clinical trials underway.
Target Audience
The primary target audience includes patients with solid tumors and other cancers, as well as individuals with liver diseases, neurological disorders, and immunological conditions, along with the healthcare providers who treat them.
Features
- LMT (LISCure Microbiology-based Technology) platform for drug discovery and analysis
- Therapeutic screening platform for identifying promising microbial candidates
- Microbial optimization platform for enhancing the therapeutic potential of microorganisms
- Microbiome database platform for comprehensive data analysis
- Development of injectable bacteria-mediated cancer immunotherapies
- Development of oral microbiome therapeutics
- Pipeline includes programs in oncology, liver diseases, neuroscience, and immunology
- Research collaborations with institutions like Mayo Clinic and Scripps Research